Suppr超能文献

衰弱和健康状况对接受经皮血管重建术的冠心病患者预后的影响。

Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization.

作者信息

Singh Mandeep, Rihal Charanjit S, Lennon Ryan J, Spertus John A, Nair K Sreekumaran, Roger Veronique L

机构信息

Divisions of Cardiovascular Diseases and Department of Health Sciences Research, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, and the Mayo Clinic and Mid America Heart Institute, Rochester, MN 55905, USA.

出版信息

Circ Cardiovasc Qual Outcomes. 2011 Sep;4(5):496-502. doi: 10.1161/CIRCOUTCOMES.111.961375. Epub 2011 Aug 30.

Abstract

BACKGROUND- Although older patients frequently undergo percutaneous coronary interventions (PCI), frailty, comorbidity, and quality of life are seldom part of risk prediction approaches. We assessed their incremental prognostic value over and above the risk factors in the Mayo Clinic risk score. METHODS AND RESULTS- Patients ≥65 years who underwent PCI were assessed for frailty (Fried criteria), comorbidity (Charlson index), and quality of life [SF-36]. Of the 628 discharged [median follow-up of 35.0 months (interquartile range, 22.7 to 42.9)], 78 died and 72 had a myocardial infarction (MI). Three-year mortality was 28% for frail patients, 6% for nonfrail patients. The respective 3-year rates of death or MI were 41% and 17%. After adjustment, frailty [hazard ratio (HR), 4.19 [95% confidence interval (CI), 1.85, 9.51], physical component score of the SF-36 (HR, 1.59; 95% CI, 1.24 to 2.02), and comorbidity, (HR, 1.10; 95% CI, 1.05, 1.16) were associated with mortality. Frailty was associated with mortality/MI (HR, 2.61, 1.52, 4.50). Models with conventional Mayo Clinic risk score had C-statistics of 0.628, 0.573 for mortality and mortality/MI, respectively. Adding frailty, quality of life, and comorbidity, the C-statistic was (0.675, 0.694, 0.671) for mortality and (0.607, 0.587, 0.576) for mortality/MI, respectively. Including frailty, comorbidities and SF-36, conferred a discernible improvement to predict death and death/MI (integrated discrimination improvement, 0.027 and 0.016, and net reclassification improvement of 43% and 18%, respectively). CONCLUSIONS- After PCI, frailty, comorbidity and poor quality of life are prevalent and are associated with adverse long-term outcomes. Their inclusion improves the discriminatory ability of the Mayo Clinic risk score derived from the routine cardiovascular risk factors.

摘要

背景——尽管老年患者经常接受经皮冠状动脉介入治疗(PCI),但衰弱、合并症和生活质量很少成为风险预测方法的一部分。我们评估了它们在梅奥诊所风险评分中超出危险因素的增量预后价值。

方法与结果——对接受PCI的65岁及以上患者进行衰弱(弗里德标准)、合并症(查尔森指数)和生活质量[SF-36]评估。在628例出院患者中[中位随访35.0个月(四分位间距,22.7至42.9)],78例死亡,72例发生心肌梗死(MI)。衰弱患者的3年死亡率为28%,非衰弱患者为6%。死亡或MI的3年发生率分别为41%和17%。调整后,衰弱[风险比(HR),4.19[95%置信区间(CI),1.85,9.51]、SF-36的身体成分评分(HR,1.59;95%CI,1.24至2.02)和合并症(HR,1.10;95%CI,1.05,1.16)与死亡率相关。衰弱与死亡率/MI相关(HR,2.61,1.52,4.50)。采用传统梅奥诊所风险评分的模型死亡率和死亡率/MI的C统计量分别为0.628和0.573。加入衰弱、生活质量和合并症后,死亡率的C统计量分别为(0.675,0.694,0.671),死亡率/MI的C统计量分别为(0.607,0.587,0.576)。纳入衰弱、合并症和SF-36后,在预测死亡和死亡/MI方面有明显改善(综合判别改善,分别为0.027和0.016,净重新分类改善分别为43%和18%)。

结论——PCI术后,衰弱、合并症和生活质量差很常见,且与不良长期预后相关。将它们纳入可提高源自常规心血管危险因素的梅奥诊所风险评分的判别能力。

相似文献

1
Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization.
Circ Cardiovasc Qual Outcomes. 2011 Sep;4(5):496-502. doi: 10.1161/CIRCOUTCOMES.111.961375. Epub 2011 Aug 30.
3
Comparison of frail patients versus nonfrail patients ≥65 years of age undergoing percutaneous coronary intervention.
Am J Cardiol. 2012 Jun 1;109(11):1569-75. doi: 10.1016/j.amjcard.2012.01.384. Epub 2012 Mar 20.
4
Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrome.
Am Heart J. 2014 Nov;168(5):784-91. doi: 10.1016/j.ahj.2014.07.022. Epub 2014 Jul 30.
6
Prognostic Value of Geriatric Conditions Beyond Age After Acute Coronary Syndrome.
Mayo Clin Proc. 2017 Jun;92(6):934-939. doi: 10.1016/j.mayocp.2017.01.018. Epub 2017 Apr 25.
7
Frailty Among Older Adults With Acute Myocardial Infarction and Outcomes From Percutaneous Coronary Interventions.
J Am Heart Assoc. 2019 Sep 3;8(17):e013686. doi: 10.1161/JAHA.119.013686. Epub 2019 Aug 31.
8
Clinical outcomes of nonagenarians with acute myocardial infarction who undergo percutaneous coronary intervention.
Eur Heart J Acute Cardiovasc Care. 2020 Aug;9(5):488-495. doi: 10.1177/2048872620921596. Epub 2020 Apr 23.
9
Clinical relevance of frailty trajectory post myocardial infarction.
Eur J Prev Cardiol. 2014 Jun;21(6):758-66. doi: 10.1177/2047487312462828. Epub 2012 Oct 1.

引用本文的文献

1
Epigenetic Biomarkers of Cardiovascular Risk in Frail Patients-A Scope Review.
Curr Issues Mol Biol. 2025 Jun 5;47(6):422. doi: 10.3390/cimb47060422.
3
Automated Real-Time Percutaneous Coronary Intervention Risk Model Leveraging Electronic Health Records.
JACC Adv. 2025 Jun 25;4(7):101865. doi: 10.1016/j.jacadv.2025.101865.
4
Role of Biological Age in the Determination of Long-Term Cause-Specific Death Following Percutaneous Coronary Interventions.
J Am Heart Assoc. 2025 Mar 4;14(5):e036876. doi: 10.1161/JAHA.124.036876. Epub 2025 Feb 26.
5
Comparison of frailty instruments for predicting mortality and prolon ged hospitalization in acute coronary syndrome patients.
PLoS One. 2025 Feb 7;20(2):e0318656. doi: 10.1371/journal.pone.0318656. eCollection 2025.
6
Development and validation of machine learning-derived frailty index in predicting outcomes of patients undergoing percutaneous coronary intervention.
Int J Cardiol Heart Vasc. 2024 Sep 21;55:101511. doi: 10.1016/j.ijcha.2024.101511. eCollection 2024 Dec.
7
Frailty and Clinical Outcomes of Ticagrelor Versus Clopidogrel in Older Adults With Acute Myocardial Infarction.
J Am Heart Assoc. 2024 Aug 6;13(15):e034529. doi: 10.1161/JAHA.124.034529. Epub 2024 Jul 26.
8
Chronological vs Biological Age in Interventional Cardiology: A Comprehensive Approach to Care for Older Adults: JACC Family Series.
JACC Cardiovasc Interv. 2024 Apr 22;17(8):961-978. doi: 10.1016/j.jcin.2024.01.284. Epub 2024 Apr 8.
9
Pre-existing frailty in the elderly and long-term mortality following percutaneous coronary intervention.
J Geriatr Cardiol. 2023 Nov 28;20(11):832-836. doi: 10.26599/1671-5411.2023.11.008.
10
Complex Percutaneous Coronary Intervention Outcomes in Older Adults.
J Am Heart Assoc. 2023 Oct 3;12(19):e029057. doi: 10.1161/JAHA.122.029057. Epub 2023 Sep 30.

本文引用的文献

1
Evolving applications for patient-centered health status measures.
Circulation. 2008 Nov 11;118(20):2103-10. doi: 10.1161/CIRCULATIONAHA.107.747568.
2
Frailty and its potential relevance to cardiovascular care.
Mayo Clin Proc. 2008 Oct;83(10):1146-53. doi: 10.4065/83.10.1146.
4
Comorbid conditions and outcomes after percutaneous coronary intervention.
Heart. 2008 Nov;94(11):1424-8. doi: 10.1136/hrt.2007.126649. Epub 2007 Oct 8.
7
Identifying frailty in hospitalized older adults with significant coronary artery disease.
J Am Geriatr Soc. 2006 Nov;54(11):1674-81. doi: 10.1111/j.1532-5415.2006.00914.x.
8
Development and validation of a prognostic index for 4-year mortality in older adults.
JAMA. 2006 Feb 15;295(7):801-8. doi: 10.1001/jama.295.7.801.
9
A risk score to predict in-hospital mortality for percutaneous coronary interventions.
J Am Coll Cardiol. 2006 Feb 7;47(3):654-60. doi: 10.1016/j.jacc.2005.09.071. Epub 2006 Jan 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验